Fighting Disease Through Innovation
Joining a clinical trial at Nuvance Health is a way to help make real progress against disease. As a clinical trial site, we test promising new therapies for diagnosing and treating many diseases.
Clinical trial listing as of July 2021
Assessment of Primary Prevention Patients Receiving an Implanted Cardiac Defibrillator – Systematic Evaluation of ATP
The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).
The purpose of this post approval study is to evaluate the long-term safety of the FDA approved St. Jude Medical Tendril MRI™ lead implanted with a SJM Brady MRI implantable pulse generator (IPG) such as the Accent MRI™, Assurity MRI™, Endurity MRI™ pacemaker, or similar model (SJM Brady MRI System) in subjects with a standard bradycardia pacing indication.
A multicenter, Randomized, Active-control study to evaluate the safety and tolerability of two blinded doses of Abenacimab compared with open label rivaroxaban in patients with Atrial Fibrillation
Product Surveillance Registry Platform
Evaluate the periodic reporting of safety and effectiveness of Medtronic market-relased products for their intended use
Long-Term Nicotine Treatment of Mild Cognitive Impairment
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients wiith, or at High Risk for, Cardiovascular Disease Who are Statin Intolerant.
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting Stents
HP-4/TIMI 65/ORION 4
A double-blind, randomized, placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with athersclerotic cardiovascular disease.
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infactrion or Stroke
D8110C00001A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
ACTIV 5/Big Effect Trial (BET-A/BET-B)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF Therapy
Giant Cell Arteritis
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
The objective of this prospective, multi-center, randomized, double-blind trial is to assess the safety and efficacy of the CARILLON Mitral Contour System in treating subjects with functional mitral regurgitation (FMR) associated with heart failure, compared to a randomized Control group which is medically managed according to heart failure guidelines.
A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled study to evaluate the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and toleratbility in HFpEF patients with acute decompensated heart failure (ADHF) who have ben stabilized duirng hospitalization and initiated in-hospital or within 30 days post discharge.
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction >40%.
Randomized Clinical Evaluation of the AccuCinch Ventricular Restoration System in Patinets who Present with Symtpomatic Heart Filure with Reduced Ejection Fraction (HFrEF).
This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without Benlysta (belimumab)
A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice.
A prospective, randomized, double-blind, sham-controlled multi-center clinical study assessing the safety and efficacy of Nerivio for the preventive treatment of migraine
Phase 4 Open Label study to evaluate treatment satisfaction with Erenumab in patients with Migraine
An Observational Study of Ocrelizumab-Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies
A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction
North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI) Registry
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
A Double-Blind, Placebo-controlled, Randomized, 18-month Phase 2A Study to Evaluate the Efficacy, Saety, Tolerability, and Pharmacokinetics of Oral UCB0599 In Study Participants with Early Parkinson's Disease
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)
A Study of Patients with Lower Extremity Acute Limb Ischemia to Remove Thrombus with the Indigo® Aspiration System